Actively Recruiting
Randomized, Double-blind, Placebo-controlled Single Dose-escalation Study of MST-931 Monoclonal Antibody in Healthy Adults
Led by Mabsoft Therapeutics (Shanghai) Co., Ltd. · Updated on 2026-11-03
32
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating MST-931, a monoclonal antibody, in a Phase 1a clinical trial involving healthy adult volunteers aged 18 to 55 years. The study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immune response of a single subcutaneous dose of MST-931 compared to a matching placebo. This research is conducted by Mabsoft Therapeutics to better understand how MST-931 behaves in the body and its potential effects. Participants are assigned randomly to one of several groups receiving different dose levels of MST-931 or a placebo. This single-dose escalation study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. The study follows a sequential design to evaluate increasing doses carefully. During the study, participants will be monitored for adverse events related to the drug over a period of up to 113 days. Researchers will collect data on how the drug is processed by the body, including measurements such as maximum concentration and elimination half-life. Participants will undergo physical exams, vital sign checks, and other safety assessments. The entire study duration for each participant may last several months to ensure thorough evaluation of safety and drug behavior.
CONDITIONS
Brief Title
Phase Ia Study of MST-931 in Healthy Adult Subjects
Research Team
C
Changlong Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here